Skip to main content
Atrás
Watch Compare

Oncotelic Therapeutics, Inc.

Calidad de datos: 100%
OTLC
OTC Manufacturing Chemicals
$0.04
$0.00 (0.00%)
Cap. Mercado: 17.70 M
Precio
$0.04
Cap. Mercado
17.70 M
Rango del Día
$0.04 — $0.04
Rango de 52 Semanas
$0.02 — $0.11
Volumen
44,500
Apertura $0.04
Promedio 50D / 200D
$0.05
20.63% below
Promedio 50D / 200D
$0.07
40.03% below

Quick Summary

Puntos Clave

Revenue declined -55.22% annually over 5 years
Negative free cash flow of -704,008.0
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 55.22%

Crecimiento

Revenue Growth (5Y)
-55.22%
Below sector avg (1.82%)
Revenue (1Y)0.00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Calidad

Return on Equity
-19.24%
Above sector avg (-53.47%)
ROIC-5.21%
Net MarginN/A
Op. MarginN/A

Seguridad

Debt / Equity
N/A
Current Ratio0.08
Interest CoverageN/A

Valoración

PE (TTM)
-10.61
Below sector avg (-1.47)
P/B Ratio1.96
EV/EBITDAN/A
Dividend YieldN/A

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Manufacturing (1364 pares)
Métrica Acción Mediana del Sector
P/E -10.6 -1.5
P/B 2.0 1.6
ROE % -19.2 -53.5
Net Margin % — -41.5
Rev Growth 5Y % -55.2 1.8
D/E — 0.3

All Fundamental Metrics
Growth
Revenue Growth (1Y) 0.00% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) -55.22% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0.0 Net Income (TTM) -1.67 M
ROE -19.24% ROA -6.09%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -704,008.0
ROIC -5.21% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 0.08
Interest Coverage N/A Asset Turnover 0.00
Working Capital -18.47 M Tangible Book Value 6.26 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -10.61 Forward P/E N/A
P/B Ratio 1.96 P/S Ratio N/A
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -3.98%
Market Cap 17.70 M Enterprise Value 17.29 M
Per Share
EPS (Diluted TTM) N/A Revenue / Share 0.00
FCF / Share 0.00 OCF / Share 0.00
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue N/A FCF Conversion 42.18%
SBC-Adj. FCF -887,750 Growth Momentum 55.22

Income Statement

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2019
Revenue 70,000.0 70,000.0 — 1.74 M —
Net Income -4.52 M -7.90 M 5.09 M -9.39 M -6.64 M
EPS (Diluted) — -0.02 0.01 — —
Gross Profit — — — — —
Operating Income -3.58 M -6.65 M -9.72 M -9.13 M -4.31 M
EBITDA — — — — —
R&D Expenses — 61,143.0 756,910.0 3.66 M 1.37 M
SG&A Expenses — — — — —
D&A — — — — —
Interest Expense — 1.04 M 2.97 M 2.00 M 749,602.0
Income Tax — — — — —

Balance Sheet

Annual, most recent first
Metric FY2024 FY2023 FY2022 FY2021 FY2020
Total Assets 26.68 M 30.01 M 36.12 M 23.61 M 23.66 M
Total Liabilities 19.20 M 18.40 M — — —
Shareholders' Equity 8.25 M 12.13 M 19.41 M 7.96 M 11.77 M
Total Debt 2.42 M 1.77 M 390,050.0 359,262.0 95,000.0
Cash & Equivalents — 170,405.0 241,452.0 568,769.0 474,019.0
Current Assets 134,211.0 271,737.0 303,164.0 627,295.0 615,636.0
Current Liabilities 19.20 M 16.50 M 16.92 M 15.45 M 11.18 M